CST, 66058SF, Fatty Acid Synthase (C20G5) Rabbit Monoclonal Antibody (BSA and Azide Free)

Monoclonal Antibody for studying FASN. Validated for WB,IHC,IF,F. Highly specific and rigorously validated in-house, Fatty Acid Synthase (C20G5) Rabbit Monoclonal Antibody (BSA and Azide Free) (CST #66058) is ready to ship. Product Usage Information This product is the carrier free version of product #3180. All data were generated using the same antibody clone in the standard formulation which contains BSA and glycerol. This formulation is ideal for use with technologies requiring specialized or custom antibody labeling, including fluorophores, metals, lanthanides, and oligonucleotides. It is not recommended for ChIP, ChIP-seq, CUT&RUN or CUT&Tag assays. If you require a carrier free formulation for chromatin profiling, please contact us . Optimal dilutions/concentrations should be determined by the end user. BSA and Azide Free antibodies are quality control tested by size exclusion chromatography (SEC) to determine antibody integrity. Formulation Supplied in 1X PBS (10 mM Na 2 HPO 4 , 3 mM KCl, 2 mM KH 2 PO 4 , and 140 mM NaCl (pH 7.8)). BSA and Azide Free. For standard formulation of this product see product # 3180 Storage Store at -20°C. This product will freeze at -20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles. A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance. Specificity / Sensitivity Fatty Acid Synthase (C20G5) Rabbit Monoclonal Antibody (BSA and Azide Free) detects endogenous levels of total fatty acid synthase protein. Species Reactivity: Human, Mouse, Rat Source / Purification Fatty Acid Synthase (C20G5) Rabbit mAb is produced by immunizing rabbits with a synthetic peptide around Gly46 corresponding to the sequence of human fatty acid synthase. Background Fatty acid synthase (FASN) catalyzes the synthesis of long-chain fatty acids from acetyl-CoA and malonyl-CoA. FASN is active as a homodimer with seven different catalytic activities and produces lipids in the liver for export to metabolically active tissues or storage in adipose tissue. In most other human tissues, FASN is minimally expressed since they rely on circulating fatty acids for new structural lipid synthesis (1). According to the research literature, increased expression of FASN has emerged as a phenotype common to most human carcinomas. For example, in breast cancer, immunohistochemical staining showed that the levels of FASN are directly related to the size of breast tumors (2). Research studies also showed that FASN is highly expressed in lung and prostate cancers and that FASN expression is an indicator of poor prognosis in breast and prostate cancer (3-5). Furthermore, inhibition of FASN is selectively cytotoxic to human cancer cells (5). Thus, increased interest has focused on FASN as a potential target for the diagnosis and treatment of cancer as well as metabolic syndrome (6,7). Alternate Names [Acyl-carrier-protein] S-acetyltransferase; [Acyl-carrier-protein] S-malonyltransferase; 3-hydroxyacyl-[acyl-carrier-protein] dehydratase; 3-hydroxypalmitoyl-[acyl-carrier-protein] dehydratase; 3-oxoacyl-[acyl-carrier-protein] reductase; 3-oxoacyl-[acyl-carrier-protein] synthase; Acyl-[acyl-carrier-protein] hydrolase; Enoyl-[acyl-carrier-protein] reductase; FAS; FASN; Fatty acid synthase; MGC14367; MGC15706; OA-519; Oleoyl-[acyl-carrier-protein] hydrolase; SDR27X1; short chain dehydrogenase/reductase family 27X, member 1; Type I fatty acid synthase Specification REACTIVITY: H M R SENSITIVITY: Endogenous MW (kDa): 273 Source/Isotype: Rabbit IgG